In this issue:
Adalimumab-induced paradoxical psoriasis treated with IL-17/IL-23 inhibitors
Do biologic treatments for psoriasis lower the risk of psoriatic arthritis?
Omalizumab in the treatment of bullous pemphigoid
Response to IL-17A inhibitors according to prior biologic exposures
Risk of paradoxical eczema with biologics for psoriasis
Dupilumab-associated lymphoid reactions in atopic dermatitis
Real-world effectiveness of risankizumab in moderate-to-severe psoriasis
Risk of infection in hidradenitis suppurativa patients on immunomodulators or biologics
Impacts of biologic treatment on metabolic profiling in psoriasis
Long-term use of upadacitinib for atopic dermatitis
Please login below to download this issue (PDF)